Product Pipeline
 It is widely known that the androgen receptor (AR) and androgens (male hormones) play a complex role in the etiology of many different diseases. These include several well documented physiological responses involving AR mediated changes in cellular function which impact prominent developmental, psychological, and disease states in both men and women.
AndroScience’s drug development pipeline is categorized according to dermatological or systemic applications of the ARD enhancer compounds. Lead dermatological indications include the clinical stage acne and alopecia programs with a third topical indication in wound healing nearing completion of preclinical development. Systemic indications center on prostate related conditions including prostate cancer and benign prostatic hyperplasia. Kennedy’s Disease, an orphan drug indication is also under active preclinical development and demonstrates tremendous therapeutic potential in treating this devastating rare disease that causes by AR mutation.
- Dermatology Clinical Indications
- Achieves greater efficacy through;
- lowers androgen mediated sebaceous gland hyperplasia and inflammation in acne and prevents androgen from acting on hair follicles in alopecia.
- Topically applied – fewer expected side effects and potential for both male and female patients
- Role in combination therapy
- Systemic Indications
- Achieves greater efficacy through;
- not competing with endogenous androgens binding to AR
- ARD enhancer possesses no “agonistic (or androgenic)” activity, thus may prevent tumor from become “hormone-refractory”, and can be uses to treat refractory tumor.
- Treatment would circumvent other non-ligand factors that could activate AR related disease progression via different activation pathways;
|